歡迎來到上海通蔚!

021-54845833/15800441009

品質(zhì)保證 · 通蔚試劑

當(dāng)前位置: 首頁 > 科研產(chǎn)品 > 科研抗體 > 一抗 > 兔抗F13B多克隆抗體
  • 兔抗F13B多克隆抗體

    規(guī)格:
    數(shù)量:

    購買數(shù)量

    價格:
    • 品牌 : 通蔚生物
    • 目錄號 : TW20135
    • 應(yīng)用 : 僅供科研使用
    • 保存條件 : 低溫保存
    • 貨期 : 現(xiàn)貨
    • 商品庫存:75
  • 商品詳情
  • 參考文獻(xiàn)
  • 說明書下載
  • 商品評論0
  • 相關(guān)產(chǎn)品


中文名稱:兔抗F13B多克隆抗體 

英文名稱: Anti-F13B rabbit polyclonal antibody

別      名: coagulation factor XIII B chain; FXIIIB

相關(guān)類別: 一抗

儲      存: 冷凍(-20℃)

宿      主: Rabbit

抗      原: F13B

反應(yīng)種屬: Human

標(biāo)  記 物: Unconjugate

克隆類型: rabbit polyclonal

技術(shù)規(guī)格

Background:

This gene encodes coagulation factor XIII B subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as a plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon activation by the cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.

Applications:

ELISA, IHC

Name of antibody:

F13B

Immunogen:

Synthetic peptide of human F13B

Full name:

coagulation factor XIII B chain

Synonyms:

FXIIIB

SwissProt:

P05160

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human cervical cancer

IHC Recommend dilution:

30-150